Spots Global Cancer Trial Database for Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer

Official Title: Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer

Study ID: NCT03451812

Conditions

Prostate Adenocarcinoma

Interventions

Study Description

Brief Summary: Primary objective: To correlate the blood/urine metabolomic biomarkers with PET/MR imaging. Secondary objectives: 1. To evaluate the sensitivity and specificity of the PET/MR in diagnosis of prostate cancer. 2. To examine the diagnostic performance among subgroups of defined high-risk and low-risk subjects. 3. To interrogate the metabolomic alterations with the molecular PET/MR to develop workable panel biomarkers.

Detailed Description: According to 2015 National Comprehensive Cancer Network (NCCN) guideline, medical imaging plays important roles for detection and staging for PCa, in addition to blood or urine biomarkers. Although there are a number of very different diagnostic imaging methods, e.g. transrectal ultrasound (TRUS), computed tomography (CT), magnetic resonance (MR) imaging and spectroscopy, or 18F-FDG positron emission tomography (PET), none of these have gained a dominant role as the optimum method for all clinical scenarios.The recently added armamentarium, PET/MR, might improve diagnosis in this regard. Therefore, we conduct this trial to identify the ability of \[11C\]Choline PET/MR to evaluate the patients with prostate cancer, especially under the circumstance of elevated PSA level.